• 1. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 2. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 3. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 4. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 5. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034

Introduction to 2,2,2-trifluoro-1-(1-methyl-1H-indol-7-yl)ethan-1-ol (CAS No. 2228964-24-5)

2,2,2-trifluoro-1-(1-methyl-1H-indol-7-yl)ethan-1-ol, identified by the Chemical Abstracts Service Number (CAS No.) 2228964-24-5, is a fluorinated indole derivative that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound represents a novel scaffold with potential applications in drug discovery, particularly in the development of bioactive molecules targeting neurological and inflammatory pathways. The structural features of this molecule, including its trifluoromethyl group and indole core, contribute to its unique pharmacological profile and make it a subject of interest for further investigation.

The indole moiety is a well-documented pharmacophore in medicinal chemistry, known for its role in modulating various biological processes. Specifically, indole derivatives have been extensively studied for their interactions with serotonin receptors, as well as their potential in treating conditions such as depression, anxiety, and neurodegenerative disorders. The presence of a trifluoromethyl group at the 2-position of the ethyl chain enhances the lipophilicity and metabolic stability of the molecule, which are critical factors in drug design. This modification is particularly relevant in modern pharmaceutical development, where optimizing pharmacokinetic properties is essential for achieving therapeutic efficacy.

In recent years, there has been growing interest in fluorinated compounds due to their ability to improve drug-like properties such as solubility, bioavailability, and binding affinity. The fluorine atom introduces electronic and steric effects that can fine-tune the interaction between a drug candidate and its biological target. For instance, fluorine substitution can increase metabolic resistance to enzymatic degradation, thereby prolonging the half-life of a drug. This property is particularly valuable in chronic disease management, where sustained therapeutic levels are required.

The compound 2,2,2-trifluoro-1-(1-methyl-1H-indol-7-yl)ethan-1-ol combines these structural elements into a single molecular framework, making it an attractive candidate for further exploration. The methyl group on the indole ring further diversifies its chemical space and may influence its binding interactions with biological targets. This combination of features suggests that the molecule could exhibit multiple modes of action or exhibit enhanced selectivity over existing therapeutic agents.

Recent advancements in computational chemistry and high-throughput screening have facilitated the rapid identification of promising drug candidates. The structural motifs present in 2,2,2-trifluoro-1-(1-methyl-1H-indol-7-yl)ethan-1-ol align well with known pharmacophores associated with therapeutic success. For example, indole derivatives have been successfully incorporated into drugs targeting serotonin receptors (e.g., SSRIs), dopamine pathways (e.g., antipsychotics), and other neurotransmitter systems. The trifluoromethyl group further enhances these interactions by improving binding affinity and reducing off-target effects.

In addition to its potential in central nervous system (CNS) applications, this compound may also have relevance in treating inflammatory conditions. Fluorinated indole derivatives have been shown to modulate inflammatory pathways by interacting with nuclear receptors such as peroxisome proliferator-activated receptors (PPARs). The unique structure of CAS No. 2228964-24-5 suggests that it could serve as a lead compound for developing novel anti-inflammatory agents with improved efficacy and reduced side effects.

The synthesis of this compound involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Advanced synthetic techniques such as palladium-catalyzed cross-coupling reactions are often employed to construct the indole core efficiently. The introduction of the trifluoromethyl group can be achieved through halogen-metal exchange followed by fluorination reactions using appropriate reagents like Selectfluor or DAST (diethylaminosulfur trifluoride). These synthetic strategies highlight the compound's complexity but also demonstrate its feasibility for large-scale production if needed.

Evaluation of the pharmacological activity of CAS No. 2228964-24-5 would typically involve both in vitro and in vivo studies. In vitro assays could assess interactions with relevant biological targets such as serotonin receptors (5-HT1A, 5-HT2A), PPARs (PPARα, PPARγ), or other enzymes involved in inflammation pathways. In vivo studies would provide insights into the compound's efficacy and safety profiles using animal models relevant to neurological or inflammatory diseases. Preliminary data from these studies could guide further optimization efforts toward developing a lead candidate for clinical development.

The growing body of literature on fluorinated indole derivatives underscores their potential as therapeutic agents. For instance, recent studies have demonstrated that certain fluorinated indoles exhibit potent antidepressant-like effects in animal models by modulating serotonin receptor activity. Similarly, other derivatives have shown anti-inflammatory properties through activation or antagonism of nuclear receptor pathways. These findings support the hypothesis that CAS No. 2228964-24-5 could be a valuable addition to this class of compounds.

From an industrial perspective, 2, CAS No. 2228964-24-5 represents an opportunity for pharmaceutical companies to explore novel chemical space with potential therapeutic benefits. Its unique structural features make it distinct from existing drugs on the market while retaining known pharmacophoric elements associated with successful drugs. As research continues to uncover new biological targets and mechanisms underlying disease pathogenesis, compounds like this one will play an increasingly important role in addressing unmet medical needs.

In conclusion, CAS No. 2228964-24-5, corresponding to 2, trifluoro-ethanol/methylindole derivative, is a promising scaffold with potential applications across multiple therapeutic areas including neurology and inflammation management.
Its structural complexity,
functional groups,
and alignment with known pharmacophores make it an intriguing subject for further research.
With continued investigation,
this compound has
the
potential
to
contribute
to
the
development
of
novel
therapeutics.
,
,
,
,
,
,
,

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)